228 related articles for article (PubMed ID: 25829188)
1. Ex vivo and in vitro production of pro-inflammatory cytokines in Blau syndrome.
Galozzi P; Negm O; Greco E; Alkhattabi N; Gava A; Sfriso P; Fairclough L; Todd I; Tighe P; Punzi L
Reumatismo; 2015 Mar; 66(4):277-84. PubMed ID: 25829188
[TBL] [Abstract][Full Text] [Related]
2. Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice.
Dugan J; Griffiths E; Snow P; Rosenzweig H; Lee E; Brown B; Carr DW; Rose C; Rosenbaum J; Davey MP
J Immunol; 2015 Jan; 194(1):349-57. PubMed ID: 25429073
[TBL] [Abstract][Full Text] [Related]
3. A Case of Blau Syndrome with NOD2 E383K Mutation.
Harada J; Nakajima T; Kanazawa N
Pediatr Dermatol; 2016 Nov; 33(6):e385-e387. PubMed ID: 27339507
[TBL] [Abstract][Full Text] [Related]
4. Novel NOD2 Mutation in Early-Onset Inflammatory Bowel Phenotype.
Girardelli M; Loganes C; Pin A; Stacul E; Decleva E; Vozzi D; Baj G; De Giacomo C; Tommasini A; Bianco AM
Inflamm Bowel Dis; 2018 May; 24(6):1204-1212. PubMed ID: 29697845
[TBL] [Abstract][Full Text] [Related]
5. The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity.
Martin TM; Zhang Z; Kurz P; Rosé CD; Chen H; Lu H; Planck SR; Davey MP; Rosenbaum JT
Arthritis Rheum; 2009 Feb; 60(2):611-8. PubMed ID: 19180500
[TBL] [Abstract][Full Text] [Related]
6. Blau syndrome NOD2 mutations result in loss of NOD2 cross-regulatory function.
Mao L; Dhar A; Meng G; Fuss I; Montgomery-Recht K; Yang Z; Xu Q; Kitani A; Strober W
Front Immunol; 2022; 13():988862. PubMed ID: 36189261
[TBL] [Abstract][Full Text] [Related]
7. Anti-TNF treatment corrects IFN-γ-dependent proinflammatory signatures in Blau syndrome patient-derived macrophages.
Kitagawa Y; Kawasaki Y; Yamasaki Y; Kambe N; Takei S; Saito MK
J Allergy Clin Immunol; 2022 Jan; 149(1):176-188.e7. PubMed ID: 34175136
[TBL] [Abstract][Full Text] [Related]
8. NOD2/CARD15 genotype influences MDP-induced cytokine release and basal IL-12p40 levels in primary isolated peripheral blood monocytes.
Beynon V; Cotofana S; Brand S; Lohse P; Mair A; Wagner S; Mussack T; Ochsenkühn T; Folwaczny M; Folwaczny C; Glas J; Török HP
Inflamm Bowel Dis; 2008 Aug; 14(8):1033-40. PubMed ID: 18383179
[TBL] [Abstract][Full Text] [Related]
9. Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations.
Li J; Moran T; Swanson E; Julian C; Harris J; Bonen DK; Hedl M; Nicolae DL; Abraham C; Cho JH
Hum Mol Genet; 2004 Aug; 13(16):1715-25. PubMed ID: 15198989
[TBL] [Abstract][Full Text] [Related]
10. A Novel NOD2-associated Mutation and Variant Blau Syndrome: Phenotype and Molecular Analysis.
Ebrahimiadib N; Samra KA; Domina AM; Stiles ER; Ewer R; Bocian CP; Foster CS
Ocul Immunol Inflamm; 2018; 26(1):57-64. PubMed ID: 27419275
[TBL] [Abstract][Full Text] [Related]
11. Brief Report: First Identification of Intrafamilial Recurrence of Blau Syndrome due to Gonosomal NOD2 Mosaicism.
Mensa-Vilaro A; Cham WT; Tang SP; Lim SC; González-Roca E; Ruiz-Ortiz E; Ariffin R; Yagüe J; Aróstegui JI
Arthritis Rheumatol; 2016 Apr; 68(4):1039-44. PubMed ID: 26606664
[TBL] [Abstract][Full Text] [Related]
12. Immune regulation of hydrogen sulfide in children with acute lymphoblastic leukemia.
Du S; Jia Y; Tang H; Sun Y; Wu W; Sun L; Du J; Geng B; Tang C; Jin H
Chin Med J (Engl); 2014; 127(21):3695-9. PubMed ID: 25382321
[TBL] [Abstract][Full Text] [Related]
13. Blau Syndrome: NOD2-related systemic autoinflammatory granulomatosis.
Takada S; Saito MK; Kambe N
G Ital Dermatol Venereol; 2020 Oct; 155(5):537-541. PubMed ID: 32618442
[TBL] [Abstract][Full Text] [Related]
14. Potential Benefits of TNF Targeting Therapy in Blau Syndrome, a NOD2-Associated Systemic Autoinflammatory Granulomatosis.
Matsuda T; Kambe N; Takimoto-Ito R; Ueki Y; Nakamizo S; Saito MK; Takei S; Kanazawa N
Front Immunol; 2022; 13():895765. PubMed ID: 35711422
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of inflammatory cytokine secretion by human alveolar macrophages.
Losa García JE; Rodríguez FM; Martín de Cabo MR; García Salgado MJ; Losada JP; Villarón LG; López AJ; Arellano JL
Mediators Inflamm; 1999; 8(1):43-51. PubMed ID: 10704089
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotyping in peripheral blood mononuclear cells, aqueous humour and vitreous in a Blau syndrome patient caused by a novel NOD2 mutation.
Jimenez-Martinez MC; Cruz F; Groman-Lupa S; Zenteno JC
Int J Immunogenet; 2011 Jun; 38(3):233-42. PubMed ID: 21320290
[TBL] [Abstract][Full Text] [Related]
17. A Novel Pathogenic
Rodrigues FG; Petrushkin H; Webster AR; Bickerstaff M; Moraitis E; Rowczenio D; Aróstegui JI; Westcott M
Ophthalmic Genet; 2021 Dec; 42(6):753-764. PubMed ID: 34251956
[TBL] [Abstract][Full Text] [Related]
18. Disease activity and cytokine production in mitogen-stimulated peripheral blood mononuclear cells from patients with rheumatoid arthritis.
Uppal SS; Raghupathy R; Hayat SJ; Longenecker JC; Abraham M; Rawoot P
Med Princ Pract; 2010; 19(1):33-9. PubMed ID: 19996617
[TBL] [Abstract][Full Text] [Related]
19. Pluripotent stem cell models of Blau syndrome reveal an IFN-γ-dependent inflammatory response in macrophages.
Takada S; Kambe N; Kawasaki Y; Niwa A; Honda-Ozaki F; Kobayashi K; Osawa M; Nagahashi A; Semi K; Hotta A; Asaka I; Yamada Y; Nishikomori R; Heike T; Matsue H; Nakahata T; Saito MK
J Allergy Clin Immunol; 2018 Jan; 141(1):339-349.e11. PubMed ID: 28587749
[TBL] [Abstract][Full Text] [Related]
20. Pro-inflammatory adjuvant properties of pigment-grade titanium dioxide particles are augmented by a genotype that potentiates interleukin 1β processing.
Riedle S; Pele LC; Otter DE; Hewitt RE; Singh H; Roy NC; Powell JJ
Part Fibre Toxicol; 2017 Dec; 14(1):51. PubMed ID: 29216926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
